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Abstract
Introduction: Varying intensity of advance care planning (ACP) interventions at the population level has not been
compared among seriously ill patients in primary care. This project will implement, test, and disseminate real-
world scalable ACP interventions among primary care clinics across three University of California Health systems.
The three ACP interventions are (1) distribution of an advance directive (AD) with targeted ACP messaging,
(2) the AD, messaging, plus prompting patients to engage with the Prepare For Your Care website (PREPARE),
and (3) the AD, messaging, PREPARE, plus Care Coordinator engagement with patients and clinicians.
Methods: We will identify a population cohort of seriously ill primary care patients and implement the ACP
interventions using electronic health record (EHR) patient portals and postal mailings. Forty-five clinics across
the three health systems will be cluster randomized to one of the three ACP interventions. The primary outcome
for the population cohort is AD or Physician Orders for Life-Sustaining Treatment documentation in the EHR.
A subset of the population cohort will be surveyed to assess patient-centered outcomes, including care con-
sistent with goals at baseline, 12 months, and 24 months. Caregivers will be interviewed if patients are unable to
be surveyed or die. ACP documentation, goal concordant care, and among decedents, health care utilization will
be compared among intervention arms.
Study Implementation: Challenges and Contributions: The project is guided by a Study Advisory Group and
Community Advisory Groups at each site to ensure rigorous patient-centered methods and consistency of
implementation. Intervention fidelity will be evaluated using the Reach, Efficacy, Adoption, Implementation,
and Maintenance (RE-AIM) framework. Challenges to implementation of this three-site health system trial and
to intervention fidelity stem from site/clinic/system cultures, increasing attention to end-of-life care from payers
and regulators, and growing pressures by health systems to implement ACP interventions. Stakeholder en-
gagement is required to ensure consistent interventions across sites.
Keywords: advance care planning; advance directives; population health
Background
Seriously ill patients commonly receive treatments atthe end of life that are not guided by their values and
goals,1,2 and their families often sustain financial3 and emo-
tional injury.4 Advance care planning (ACP)—a process of
understanding and sharing personal values, life goals, and
preferences regarding future medical care5—is associated
with earlier hospice referral, better end-of-life quality for
patients, and better bereavement adjustment for families.1
Experimental evidence shows that ACP interventions in-
crease completion of advance directives (ADs), increase dis-
cussions about care preferences, and concordance between a
patient’s preferences and end-of-life care.6 Multicomponent
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interventions, many of which are not feasible in real-world
settings, have been shown to increase the likelihood of AD
completion,7 but much of this work has focused on hospital-
ized patients8 and those with cancer.9 A systematic review of
ACP interventions found decreased use of life-sustaining
treatment and increased hospice and palliative care but con-
cluded that more experimental designs and community studies
are needed.10
While studies have demonstrated efficacy of easy-to-use
patient-facing interventions,11,12 the comparative effective-
ness of ACP interventions has not been tested in randomized
trials at the health system level and population level and in
primary care,13 where clinicians are already overburdened
with the complex management of seriously ill patients. This
is important because health systems need feasible evidence-
based ACP interventions.
The conceptual framework of this study is based on the
ACP model of Sudore and collegues,14,15 which proposes
that behavior change can be influenced through interventions
that affect knowledge, self-efficacy, and readiness to engage
in ACP. Easy-to-read ADs and the Prepare For Your Care
(PREPARE) online program are based on this framework and
have been shown to increase patients’ readiness to engage in
ACP.11,12,16,17 One-on-one facilitation has also been shown
to increase ACP documentation and engagement18 but is
often costly and time consuming (Fig. 1). These interventions
have not previously been compared.
Objectives and hypotheses
The goal of this pragmatic trial is to implement, test, and
disseminate real-world scalable ACP interventions among
primary care clinics across three University of California
(UC) Health systems with the following study aims.
Aim 1. Guided by stakeholders at each site, determine
barriers, facilitators, and best workflow plans to implement
the three ACP interventions.
Aim 2. Implement the three ACP interventions in pri-
mary care clinics among patients with serious illness using
a cluster randomized design across the three UC Health
systems: distribution of an AD (arm 1), distribution of the
AD plus prompting the patient to engage with the PRE-
PARE website (arm 2), and AD distribution plus PREPARE
plus a nonclinician Care Coordinator (CC) intervention
(arm 3).
Aim 3. Compare the effectiveness of the three interven-
tions on formal ACP documentation (primary outcome)
across the three UC Health systems and, among a subset of
patients and caregivers, assess the patient-reported outcomes
of goal-concordant care and ACP engagement.
We hypothesize that therewill be additive improvement from
arm 1 to arm 2 to arm 3 on formal ACP documentation (primary
outcome) at the population level and receipt of goal-concordant
treatment among the subset of surveyed patients and caregivers.
Methods
Study design
Study overview. In concert with patient and clinician
stakeholder partners, this project will develop clinic level
implementation strategies for the three evidence-based ACP
intervention comparators. Using a cluster randomized design,
we will implement real-world system-wide ACP interven-
tions in primary care clinics for a seriously ill population
cohort across the three UC Health systems. The effect of the
interventions will be evaluated by formal ACP documenta-
tion (Fig. 2). To evaluate a more detailed set of outcomes
including goal-concordant treatment and ACP engagement, a
subset of patients in a research cohort will be surveyed and
their medical records will be reviewed. Patients’ caregivers
will be interviewed if patients are unable or if the patient dies
during the follow-up period (Fig. 3).
Setting. Thirty-six UCLA primary care clinics, 6 UCI
clinics, and 3 UCSF clinics. Five additional clinics at UCLA
will be randomized to arm 1 or 2 only because these clinics do
not have a CC.
Population. The population cohort (estimated N= 6400)
includes patients aged 18 years or older who have serious ill-
ness and attended at least two primary care office visits during
the prior 12 months. Patients are included regardless of prior
ACP documentation. Serious illness was defined using ad-
ministrative billing codes, encounter data, and clinical infor-
mation available in the electronic health record (EHR)
(Table 1). The definition of serious illness requires an at-risk
medical diagnosis (cancer, heart failure, chronic obstructive
pulmonary disease, end-stage liver disease, end-stage renal
disease, or amyotrophic lateral sclerosis) linked with advanced
age or a level of severity such that ACP would be a priority,
defined as: (1) poor short-term survival prognosis or (2) de-
veloping incapacity or (3) worsening functional status or (4)
FIG. 1. Mediators and factors associated with ACP. ACP, advance care planning.
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high burden of disease (causing excessive suffering, which
may be related to health care utilization). To validate the ser-
ious illness definition, chart abstraction of 306 patients across
the three health systems confirmed that 301 (98%)met theACP
Priority criteria.
The research cohort is a subset of the population cohort
who will be surveyed and includes 900 patients (300 in each
of the three study arms) who have no formal ACP docu-
mentation in the EHR in the past three years. During the
consent process, individuals will be asked to designate and
provide contact information for a caregiver.
Interventions. Interventions are conceptualized as
system-based quality improvement efforts. Each intervention
arm builds on the prior arm, so intervention arm 2 includes
the components of intervention arm 1, and arm 3 includes the
components of arm 2. The intervention will only be delivered
to patients in the population cohort who have no formal ACP
documentation in the EHR in the past three years. We chose a
three-year time frame because surrogate specification and
ACP preferences change over time, especially for individuals
with serious illness.19
While these interventions are based on studies that im-
plemented an intensive one-on-one introduction of an easy-
to-read AD and the PREPARE website in an office setting,
the proposed interventions aim to introduce these interven-
tions using system-based mechanisms and reminders. The
ACP intervention will use the Epic patient portal and postal
service mailing three weeks before a nonurgent primary care
appointment. Patients will receive an introductory letter from
the health system, in English or Spanish, encouraging pa-
tients to engage in ACP. The messaging and letters were
developed with more than 100 stakeholders across all sites.
The message introduces ACP, the purpose of the AD and
instructions for completing and returning it, and a prompt to
discuss ACP at their primary care visit. ACP interventions
are tied to primary care appointments. Patients without a
scheduled appointment six months after the initiation of the
ACP intervention will receive the intervention regardless of
an upcoming appointment (i.e., bulk mailing). A reminder to
bring the AD to clinic will be delivered before the scheduled
clinic visit using automated patient portal messages or tele-
phone calls, if available and according to local practice. We
will resend the intervention to patients (e.g., a booster) if they
do not have EHR ACP documentation six months after the
initial intervention, and a reminder will be sent at six month
intervals to those lacking ACP documentation.
The ACP intervention for patients in arm 1 includes a
mailed AD or link to an AD accompanying the message.
Arms 2 and 3 will include a referral to the PREPARE website
FIG. 2. UC ACP study flow diagram: population cohort. ACP, advance care planning; AD, advance directive; UC,
University of California.
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(www.prepareforyourcare.org) via a link in the patient portal
or the postal letter and a pamphlet. Website Uniform Re-
source Locators specific to each arm will track website use
for implementation monitoring.
Patients in arm 3 will be contacted by a CC, who is a
nonclinician health care navigator. Most eligible clinics
across the sites have CCs providing health navigation to
high-risk patients; this intervention will add ACP to their rep-
ertoire. CCs will be apprised of patients receiving the inter-
vention and will: (1) evaluate AD completion; (2) introduce
ACP to the patient and facilitate referral to the PREPARE
website, access ADs, and answer basic ACP questions or
refer to the patient’s primary care provider (PCP); (3) facil-
itate completion and collection of ACP documents; (4) notify
PCPs about obstacles to ACP, and (5) facilitate PCP con-
sideration of Physician Orders for Life-Sustaining Treatment
(POLST) in patients with a hospital discharge code status of
do not resuscitate (DNR). CCs will be trained and provided
scripts and checklists. The eight-hour training will introduce
ACP and ACP documents and include role play scenarios
with actors.
We will offer 20–30-minute ACP educational sessions for
each primary care clinic, tailored to study arm, about ACP
basics and ACP conversations, documentation, and billing.
Randomization. A statistician not involved in recruit-
ment or data collection will randomize each clinic to an in-
tervention arm. We will use constrained randomization to
ensure that clinics with the same CC are not randomized
to different arms and that each treatment arm has a similar
number of patients, age of patients, and rates of AD com-
pletion overall and in the past three years.
Blinding. Since interventions are implemented in the
context of a pragmatic quality improvement project at the
FIG. 3. UC ACP study flow diagram: research cohort.
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Table 1. Advanced Illness Definitions and Identification Criteria
Advanced illness group Advanced illness group definition Identification criteria
Advanced cancer Solid tumor or hematologic cancer that
is incurable
(Problem List ICD code for advanced
cancera AND oncology visit in the last
12 months)
OR
(Ambulatory encounter billing ICD code for
advanced cancera AND chemotherapy in
the last 2 Years)
Advanced HF HF that substantially affects the patient’s
function ([{Shortness of breath or
weakness or chest pain or ectopy with
exertion or edema affecting function or
cannot do activities} and not due to
another cause] or class 3 or 4) AND last
known LVEF <31%
(Problem List or Ambulatory encounter
billing ICD code for HFb in the past year
AND any left ventricular ejection fraction
over the last 3 years <31%)
OR
(Problem List for HFb AND at least 1
hospital admission with an ICD code
for HFb)
Advanced COPD COPD that substantially affects the
patient’s function ([shortness of breath
with exertion or cannot do activities
and not due to another cause] or GOLD
class 3 or 4) and FEV1 < 50% predicted
OR O2-dependent at home (all the time
or for exertion but not just at night)
Problem List ICD code for COPDc
AND
[(V or Z code for home oxygend) OR (At
least 1 hospital admission with an ICD
code for COPDc in the last year)]
Decompensated liver disease Cirrhosis with evidence of
decompensation represented by ascites,
esophageal variceal bleeding,
hepatorenal syndrome, or hepatic
encephalopathy
Problem List ICD code for cirrhosise
AND
[hepatic decompensationf measured by:
(Problem List or Ambulatory encounter
billing ICD code) OR (MELD >18)]
End-stage renal disease Chronic kidney disease on hemodialysis
or hemodialysis and/or renal transplant
being actively considered or history of
renal transplant
(Problem List AND Ambulatory encounter
billing ICD-10 code for end stage renal
diseaseg)
OR
[(Problem List OR Ambulatory encounter
billing ICD code for end stage renal
diseaseg) AND (Nephrology visit in last
year-inpatient or ambulatory)]
ALS ALS with progressive symptoms
impacting functional status
Problem List AND Ambulatory encounter
billing ICD code for ALSh
Vulnerable elder with serious
illness
Age 75 years or older with at least one
serious illness
Age 75 years or older AND (Problem List
ICD for advanced cancer,a heart
failure,b COPD,c cirrhosis,e end stage
renalg or ALSh)
ICD diagnoses:
aCancer: ICD-9 liver (155, 155.1, 155.2), esophagus (150, 150.1-5, 150.8-9), stomach (151, 151.1-6, 151.8-9), pancreas (157, 157.1-3,
157.8-9), peritoneum (158, 158.8-9), brain (191, 191.1-9), secondary malignant neoplasms (197, 197.1-8, 198, 198.1-8, 198.81-2, 198.89),
malignant pleural effusion (511.81), malignant ascites (789.51), disseminate malignant neoplasm (199), leptomeningeal carcinomatosis
(349.2), heme malignancy (200.7, 200.71-8, 201, 201.4-7, 201.9, 202.8, 204.02, 204.12, 204.92, 205, 205.02, 205.12, 208.12). ICD-10 liver
excluding HCC (C22.1-4), esophagus (C15.3-5, C158-9), stomach (C16.0-6, C16.8-9), pancreas (C25.0-3, C25.7-9), peritoneum (C48.0-2,
C48.8), brain (C71, C71.0-9), secondary malignant neoplasms (C78.00, C78.1-2, C78.39, C78.4-7, C78.89, C79.00, C79.11, C79.19, C79.2,
C79.31-2, C79.49, C79.51-2, C79.60, C79.70, C79.81, C79.82, C79.89, C79.9), malignant pleural effusion ( J91.0), malignant ascites
(R18.0), disseminated malignant neoplasm (C80.0), leptomeningeal carcinomatosis (G96.12), heme malignancy (C81.09, C81.19, C81.29,
C81.39, C81.49, C81.79, C81.99, C85.19, C85.29, C85.89, C91.02, C91.12, C91.52, C91.62, C91.92, C91.A2, C92.02, C92.12, C95.12).
bHF: ICD-9 (428, 428.1-4, 428.21-3, 428.31-3, 428.41-3, 428.9, 398.91, 402.01, 402.11, 402.91, 404.01, 404.03, 404.11, 404.13, 404.91,
404.93); ICD-10 (I09.81, I11.0, I13.0, I13.2, I50.1, I50.9, I50.20-23, I50.30-33, I50.40-43).
cChronic obstructive lung disease: ICD-9 (491.2, 492.21-22, 493.2, 493.21-22, 496); ICD-10 ( J43.9, J44.0, J44.1, J44.9).
dOxygen: ICD-9 (V46.1-2, V46.11-14); ICD-10 ( J95.850, Z99.1, Z99.11-12, Z99.81).
eCirrhosis: ICD-9 (571.2, 571.5, 571.6); ICD-10 (K70.3, K70.30, K70.31, K70.4, K70.40, K70.41, K74.3-5, K74.60, K74.69).
fHepatic decompensation: ICD-9 encephalopathy (572.2); ICD-10 (K72.90, K72.91); hepatorenal ICD-9 (572.4); ICD-10 (K76.7);
peritonitis ICD-9 (567, 567.2, 567.21, 567.23, 567.29, 567.8, 567.89, 567.9); ICD-10 (K65.9, K67, K65.0, K65.2, K65.8); esophageal
varices: ICD-9 (456, 456.2, 456.21); ICD-10 (I85.01, I85.10, I85.11); ascites: ICD-9 (789.5, 789.51, 789.59); ICD-10 (R18.8).
gEnd-stage renal disease: ICD-9 (585.5, 585.6, V42.0, V45.1, V45.11, V45.12, V56, V56.0-3, V56.31-32, V56.8); ICD-10 (N18.5, N18.6,
Z94.0, Z99.2, Z91.15, Z49.31, Z49.01, Z49.02, Z49.32).
hALS: ICD-9 (335.2); ICD-10 (G12.21).
Cancer diagnoses from Anand et al.38
ALS, amyotrophic lateral sclerosis; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 second; GOLD,
global initiative for obstructive lung disease; HF, heart failure; ICD, International Classification of Diseases; LVEF, left ventricular ejection
fraction.
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population level, patients, clinicians, and research staff will
not be blinded to intervention allocation.
Outcome measures. Primary outcomes. The primary
outcome for the population cohort is formal ACP documen-
tation (AD, POLST, power of attorney, or out-of-hospital
DNR form) in the health system EHR using administrative
data. Validation of administrative data for ACP documenta-
tion of 306 patients compared to medical record abstraction
across the three UC sites demonstrated >95% accuracy.
The primary outcome for the research cohort is patient-
reported receipt of goal-concordant care. There is currently no
gold standard measure to assess goal concordant care; thus, we
will use the three different approacheswith survey and/or chart
data including cross-sectional care preference questions from
Study to Understand Prognosis and Preferences for Outcomes
and Risks of Treatments (SUPPORT),20 future care preference
questions from the PREPARE AD using a method to match to
chart abstraction data,21 and questions in the after death survey
tapping into goal-concordant care16,22 (Table 2).
Secondary outcomes. For the population cohort, we will
evaluate new ACP documentation since the baseline inter-
vention to 12 and 24 months. This analysis will include only
patients with no formal ACP documentation in the past three
years. In the population cohort, we will measure health care
utilization among decedents including hospitalization, in-
tensive care unit (ICU), and emergency department (ED) use.
Secondary outcomes for the research cohort include ACP
engagement (e.g., self-reported discussions and documenta-
tion) using questionnaires23 and medical record review.
Measures include ACP documentation; readiness to engage
in ACP,16 surrogate designation, discussions, and documen-
tation; desired role in decisions24; patient reports about
physician communication25; confidence and trust in future
care (Totten AM et al.)26; and caregiver reports of end-of-life
care including decisional regret.27
Recruitment and study procedures
Recruitment. Since the population cohort is part of a
quality improvement effort that includes all seriously ill primary
care patients, recruitment methods apply only to the research
cohort. PCPswill be sent a secure e-mail to obtain permission to
contact their eligible patients. PCPs will be asked to exclude
patientswith cognitive impairment, language other than English
or Spanish, or for whom the survey might cause psychological
harm. We will send two permission e-mails to physicians, after
which we will assume assent to contact their patients.
Eligible patients will bemailed a letter introducing the study,
a written consent form that also asks about a caregiver who we
may contact if needed in the future, and the survey instrument.
Patients may enroll in the study by signing the consent form,
completing the survey, and mailing it back. Included in the
introductory letter is an ‘‘opt out’’ telephone number.
Patients who do not return a survey by mail or opt out may
be contacted two weeks after the survey mailing by telephone
or e-mail to assess interest in participating. No response after
three voice messages will be considered an opt out. For pa-
tients recruited by telephone, we will exclude individuals
who cannot perform informed consent after three attempts
via teach-back.28 Surveys can be conducted by telephone or
online, per patient preference; however, a signed consent
form will be required to use the survey data.
Patients will receive a $30 gift card for each survey
(baseline, 12-month, 24-month). If the patient loses capa-
bility before the 12- or 24-month survey, the designated
caregiver, if provided by the patient, will be approached for
Table 2. Survey Measures
Survey items Baseline
12-month
patient
24-month
patient
Caregiver
after death
Patient items
Contact info X
Demographicsa X X
Experience with ACP tools (intervention) X X X
Patient engagement in ACP16 X X X X
Medical care preference current (support)20 X X X X
Care preference and future health states (PREPARE) X X X
Confidence and trust in future care X X X
Desired role in decisions24 X Xb Xb
CAHPS communication composite25 X X X
Self-rated health and QOL30 X X X X
PROMIS global physical health (GPH2)30 X X X
Depression items from PROMIS 2931 X Xb Xb
Anxiety items from PROMIS 2931 X Xb Xb
Social support32 X
Religious/spiritual29 X
Bereaved family survey33 X
Goal-concordant care22 X
Decisional regret27 X
aDemographics collected for first patient survey and, if needed, first caregiver survey.
bCaregiver version excludes these items.
ACP, advance care planning; AD, advance directive; CAHPS, Consumer Assessment of Healthcare Providers and Systems; GPH2;
PREPARE, Prepare For Your Care website with questions adapted from the easy-reading AD; PROMIS, Patient-Reported Outcomes
Measurement Information System; QOL, quality of life.
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follow-up surveys. For decedents, designated caregivers will
be approached to complete the after death survey (adminis-
tered three months after death). Caregivers will receive a $30
gift card for each completed survey.
Data collection and analysis plan
Data collection: administrative data. EHR data will be
used to identify the population cohort, administer the inter-
vention, and supply outcome information for the population
cohort including formal ACP documentation, hospitaliza-
tions, ICU stays, ED use, and to the degree available hospice
use, vital status and venue of death.
Data collection: questionnaires. For the research co-
hort, data collection will take place through written, tele-
phone, and online questionnaires. Data will be entered into
secure REDCap databases.
To characterize the research cohort, the survey will assess
demographics, religiosity and spirituality,29 self-rated health
and quality of life,30 depressive symptoms and anxiety,31 and
social support.32 For implementation fidelity evaluation, the
survey will ask about patient experience with ACP tools. The
after death survey contains modified items from the Bereaved
family survey,33 caregiver self-rated health and quality of
life,30 and other items (Table 2).
Data collection: medical records. For the research
cohort, medical records will be reviewed after the final survey
or the patient’s death. All notes will be reviewed including
clinician, social work, and pastoral care. The abstraction will
capture demographic and clinical information including co-
morbidities, content of ADs and POLST forms, and orders
concerning initiating, withholding or withdrawing resusci-
tation, and other life-sustaining treatments. Documentation
of ACP discussions, goals of care, surrogate specification,
and decision making concerning life-sustaining treatment
and end-of-life care will be abstracted to inform whether a
patient received goal-concordant care. ED, hospital, and ICU
episodes will be recorded as well as time spent in adverse
health states. A 10% sample of records will be re-abstracted
to evaluate reliability.
Data management and security. Administrative data
for the population cohort will be maintained behind UC in-
tuitional firewalls on secure servers. Survey data for patients
in the research cohort will be collected on paper and then
entered into REDCap using a unique study ID or entered into
REDCap in real time by a research assistant during telephone
or in person interview, or via an e-mail link. REDCap will be
managed at the central site and stored behind the firewall. A
unique, non-identifying patient study ID removed from any
personal health information will be stored in a secure file. All
paper surveys and consent forms will be stored in locked files
in locked research offices. The study ID will be used to store
medical record abstraction data behind the firewall.
Statistical analysis plan. Analyses will be performed in
an intention-to-treat manner to compare the three study arms.
For primary endpoints, Bonferroni correction will be applied
to account for three pairwise comparisons, and a p-value of
<0.017 will be considered statistically significant for each
comparison. SAS software will be used.34
Sample size and power. A simulation study was performed
to evaluate the statistical power of the study using initial
baseline data among 45 clinics (*6400 serious illness pa-
tients) to be randomized to 3 arms. Prior studies suggest that
similar interventions increase AD completion from 25% to
47%.35 Consistent with these studies, the PREPARE trial
demonstrated an effect size of 0.5; to account for the prag-
matic nature of the proposed trial, a conservative estimate
would be a 25% absolute increase in AD completion from
baseline. With about 37% of serious illness patients having
ADs at baseline, we expect that formal ACP documentation
will increase to 47%, 62%, and 72% for arm 1, arm 2 and arm
3, respectively. Accounting for the multiple comparisons for
the primary endpoint, we expect to have ‡80% power for all
comparisons with intraclass correlations £0.02.
Evaluation of hypotheses. For the primary outcome, cu-
mulative ACP documentation rates for the population cohort
from baseline to 12 and 24 months (or death) will be com-
pared as a difference of differences among the three study
arms. The baseline date is defined as the clinic rollout date.
Generalized estimating equation (GEE) logistic regression
models will be used for this analysis to account for patients
clustered within clinics. Covariates include, a priori, patient
age, gender, race/ethnicity, serious illness category, clinic
baseline AD completion rate, site, time (baseline, 12 months,
or 24 months), study arm, and study arm–time interaction.
We will also include any additional patient characteristics
that differ by study arm. We hypothesize that ACP docu-
mentation will increase in arm 3 more than arm 2 more than
arm 1. In the secondary analysis, new ACP documentation
will be compared among the three arms at 12 and 24 months
(or death) from baseline among patients with no formal ACP
documentation in the past three years.
For decedents in the population cohort, we will assess
hospital, ICU, and ED visits within 30 days of death between
the three study arms using the GEE logistic model with pa-
tients nested in clinics using the covariates included above.
Ethics determination
This study was approved by the UCLA Institutional Re-
view Board (IRB) (18-001612); the UCSF and UCI IRBs will
rely on the UCLA IRB.
Study Implementation: Challenges and Contributions
Patient and key stakeholder engagement
The project is guided by a Study Advisory Group (SAG)
that meets biannually with e-mail contact as needed. The
SAG includes state and national leaders in ACP and palliative
care, clinicians, patients and caregivers from each site, in-
cluding the UC Office of the President, National POLST
paradigm, Palliative Care Quality Network, Palliative Care
Research Cooperative Group, Center to Advance Palliative
Care, and National Palliative Care Research Center. Meet-
ings are coordinated with assistance of the Coalition for
Compassionate Care of California (CCCC). The SAG pro-
vides oversight to ensure that rigorous patient-centered
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methods are employed including consistency of intervention
implementation across the clinics at the three sites.
Community Advisory Groups (CAGs) at each site include
patients with serious illness, caregivers, and clinicians who
work in participating clinics. CAGs meet two to three times
each year with e-mail contact as needed. CAGs not only
review and give feedback on the protocol and materials to
ensure that they are patient-centered but also will review
project progress, evaluate enrollment efforts, and review early
study findings.
Fidelity monitoring in the context of complex
interventions
Reach, Efficacy, Adoption, Implementation, and Main-
tenance (RE-AIM36,37) of the interventions will be evaluated
over time and across clinics and sites using the measures and
sources listed in Table 3. The evaluation aims to facilitate
implementation and afford a mechanism to evaluate hetero-
geneity of effect.
Response to challenges and barriers
to study success
This project implements a coordinated system-level in-
tervention across the three UC Health systems in an area of
clinical practice that is receiving considerable attention from
payers and regulators. This translates into pressure on health
systems to implement interventions, even though evidence-
based information about intervention effectiveness and effi-
ciency is lacking. Furthermore, end-of-life health care costs
are an increasing focus of health system intervention efforts.
The project’s main challenges relate to maintaining support
for the proposed interventions at a time of change.
Health system pressure tomodify interventions. Health
systems may implement interventions in response to market
forces or influence leaders rather than evidence from tri-
als. The interventions proposed by this project are evidence
based, but comparative effectiveness data at a population
level are lacking. Keeping the three health systems focused
on the proposed interventions rather than adding additional
components has required substantial stakeholder engage-
ment to maintain buy in. This tension translated into some
clinics desiring to employ the arm 3 intervention, which
would conflict with the proposed three-arm comparative
effectiveness protocol. This required identification of a smaller
number of protected clinics to participate in this trial. Re-
dundancy in the project ensured adequate patient sample and
clinics, preserving sample size and statistical power.
Table 3. Framework for Monitoring Intervention Fidelity
RE-AIM construct Measure Data source
Reach: individuals from the target
population who participated in
the intervention
1. Number of ADs distributed 1. ADs accessed through portal link and
mailed
2. Number of patients who accessed
the PREPARE website
2. PREPARE website login data provided
through data dashboards
3. Number of patients touched by
CCs
3. CCs log of patients for whom they
introduce ACP
Efficacy: intervention impact on
outcomes
1. Population-level AD and POLST
completion
1. Data from electronic health record
2. Patient-level reports of goal-
concordant care
2. Medical record and survey data
3. Caregiver reports of end-of-life
experience and goal-concordant
care
3. Medical record and survey data
Adoption: those who adopted the
intervention
Variation among clinics and sites in
number of ADs distributed,
number of patients who accessed
the PREPARE website, and
number of patients touched by
clinical CCs
Collected as in ‘‘Reach’’ above
Implementation: extent intervention
is implemented as intended
1. Receipt of ADs 1. Patient portal recipients that accessed
message and AD link.
2. Receipt of invitation to
PREPARE website and
accessibility
2. Patient portal recipients that accessed
message and REPARE website link.
3. Interaction with CCs and
discussion with primary care
physician
3. Follow-up survey items from the research
cohort
Maintenance: extent to which
intervention is sustained over
time
Reassessment of reach, adoption,
and implementation at 6, 12, 18,
and 30 months. Reassessment of
efficacy at 6, 12, and 30 months
Collected as in ‘‘Reach, Adoption, and
Implementation’’ above
CC, care coordinator; POLST, Physician Orders for Life-Sustaining Treatment; RE-AIM, Reach, Efficacy, Adoption, Implementation,
and Maintenance.
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Secular trends. ACP is changing considerably including
addition of new billing codes, increasedmonitoring, and greater
pressure from insurers including direct-to-patient palliative
care interventions. During the intervention period, all three
health systems rolled out EHR ACP components separate from
this project. This prompted additional efforts working with
health system EHR leadership to preserve the proposed auto-
mated ACP interventions, which are built through the EHR. At
each site, we are collecting environmental changes inACP to be
able to chronicle secular trendswhen data analysis is performed.
Ensuring fidelity to the intervention across sites.
The proposed interventions depend on participation of clinics
and a build within the EHR to implement consistent inter-
ventions across sites. The sites use the same EHR but run
different versions, and there is a variable level of resource
support for build efforts across sites. The patient cohort
method is identical across sites with use of a consistent set of
International Classification of Diseases (ICD) codes and ad-
ministrative data elements that demonstrated valid patient
identification on medical record review across sites. Con-
cerning the build for automated ACP messaging and mail-
ings, the EHR developers decided together that it was most
feasible to build interventions that are ‘‘genotypically dif-
ferent, but phenotypically the same’’ meaning that the in-
tervention as seen by the patient will be identical, although
the inner working in the EHR will differ. The builders pro-
pose that this strategy is a methodological strength so that the
best EHR build can be implemented across UC Health after
study completion.
Plans for dissemination and spread
The SAG includes some of the nation’s most influential or-
ganizations involved in improving ACP and palliative care.
Their involvement will facilitate a variety of dissemination ap-
proaches, if the interventions are found to be effective. The UC
Office of the President pledged to promulgate a successful in-
tervention throughout UC Health. The Center to Advance Pal-
liative Care, California Health Care Foundation, National
POLST paradigm, and CCCC all have extensive relationships
with community organizations that can be leveraged to ensure
that study findings are implemented. We will work with the
CAGsandSAGtodesignpublic forums for sharing study results.
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